Researchers at CNRS, Université Côte d’Azur and Inserm have demonstrated a new mechanism related to the onset of migraine. They found how a mutation that causes dysfunction in a protein which inhibits neuronal electrical activity induces migraines. These results, published in Neuron on December 17, 2018, open a new path for the development of anti-migraine medicines.
Even though 15% of the adult population worldwide suffers from migraines, no long-term, effective, curative treatment has been marketed to date. Migraine episodes are related, among other factors, to electric hyperexcitability in sensory neurons. Their electrical activity is controlled by proteins that generate current called ion channels—specifically by the TRESK channel, which inhibits electrical activity. The researchers have shown that a mutation in the gene encoding for this protein causes a split between two dysfunctional proteins: one is inactive, and the other targets other ion channels (K2P2.1), inducing a intense stimulation of the neuronal electrical activity thus causing migraines.
Though researchers had already shown the hereditary nature of migraines, they did not understand the mechanism underlying them. By demonstrating that the TRESK split induces hyperexcitability in sensory neurons leading to migraine, this work—carried out at the Institut de Biologie Valrose (CNRS/Inserm/Université Côte d’Azur)—opens new research paths for the development of anti-migraine medicines.
Source: Read Full Article